Charles River Laboratories
Large Cap · Healthcare · Diagnostics & Research
$279.26−$7.38 (-2.57%)
Charles River Laboratories
Large Cap · Healthcare · Diagnostics & Research
$279.26−$7.38 (-2.57%)
Stock analysis
Get the AI take on CRL
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$144.26
High$237.86
Today $279.26
RSI (14)
83.0Overbought
03070100
Overall score
47/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$145
Current price
$279.26
Median target
$300
Highest
$318
LowHigh
Operating Record
Revenue
What to watch
- Debt exceeds cash by $2.8B, increasing balance-sheet pressure, a warning sign.
- Price / FCF: Cash generation hasn't caught up to the price tag yet.
What the market charges
Forward P/E
Middle ground · 5% below avg
22.79x
Price / sales
Reasonable · Priced reasonably against its revenue
3.34x
Price / FCF
Rich · Priced far above what its cash flow currently supports
36.07x
EV / EBITDA
Reasonable · Operating earnings make this price a stretch but plausible
19.09x
How efficiently it compounds
ROIC
Reasonable · A middling return on the capital it puts to work
8.6%
ROE
Needs attention · Unfavorable
-7.5%
Debt / equity
Middle ground · Mixed
1.05x
Current ratio
Reasonable · Just enough on hand to cover near-term bills
1.35x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $13.37B | - | -0.7% | 47 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |